Epigral Balance Sheet Health
Financial Health criteria checks 3/6
Epigral has a total shareholder equity of ₹14.0B and total debt of ₹9.0B, which brings its debt-to-equity ratio to 63.9%. Its total assets and total liabilities are ₹29.8B and ₹15.8B respectively. Epigral's EBIT is ₹5.1B making its interest coverage ratio 6.7. It has cash and short-term investments of ₹60.8M.
Key information
63.9%
Debt to equity ratio
₹8.95b
Debt
| Interest coverage ratio | 6.7x |
| Cash | ₹60.80m |
| Equity | ₹14.00b |
| Total liabilities | ₹15.79b |
| Total assets | ₹29.79b |
Recent financial health updates
No updates
Recent updates
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
Dec 18
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Jul 04Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
Apr 19Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Feb 23Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
Feb 21Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
Apr 05With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case
Sep 28Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations
May 03Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price
Nov 22Financial Position Analysis
Short Term Liabilities: EPIGRAL's short term assets (₹6.7B) do not cover its short term liabilities (₹8.5B).
Long Term Liabilities: EPIGRAL's short term assets (₹6.7B) do not cover its long term liabilities (₹7.3B).
Debt to Equity History and Analysis
Debt Level: EPIGRAL's net debt to equity ratio (63.5%) is considered high.
Reducing Debt: EPIGRAL's debt to equity ratio has reduced from 85.3% to 63.9% over the past 5 years.
Debt Coverage: EPIGRAL's debt is well covered by operating cash flow (48.3%).
Interest Coverage: EPIGRAL's interest payments on its debt are well covered by EBIT (6.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Epigral Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BP Wealth Management Private Limited |
| Meet Vora | Emkay Global Financial Services Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |